ArticleDrug design, development and therapy2018

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.

Yayi He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.